Bailing capsules and Guben Kechuan granules for stable bronchiectasis
Part of Lungs & breathing clinical trials.
This trial tests whether two Chinese herbal medicines, Bailing capsules and Guben Kechuan granules, can help people with stable bronchiectasis. It aims to reduce flare-ups and improve lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been diagnosed with bronchiectasis
- You have not had a flare-up or respiratory infection in the past 4 weeks
- You have had at least 2 flare-ups in the past year that needed treatment
- You can perform lung function tests, and your breathing test shows some airway blockage
- You are willing to use birth control during the study if you could become pregnant or get someone pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a Chinese herbal medicine called Lifei Qingchang Granules to see if it can help prevent flare-ups in people with bronchiectasis (a lung condition where airways are damaged and collect mucus). The study focuses on people whose condition is currently stable but who have had at least one flare-up in the past year.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This trial tests whether a new medication, BI 1291583, can help people with bronchiectasis reduce lung infections and symptoms. You may join if you have had at least one or two lung flare-ups in the past year.
This trial tests an inhaled medication for people with bronchiectasis, a lung condition causing chronic cough and mucus. It first checks safety in healthy volunteers, then studies how the drug works in people with bronchiectasis.
This trial tests an investigational tablet for people with chronic lung diseases like bronchiectasis, COPD, or asthma who produce at least 10 mL of sputum (mucus coughed up from the lungs) each day. The goal is to see if the drug safely reduces excess airway mucus.
This study tests whether an investigational tablet called XH-S004 can reduce flare-ups and improve symptoms in people with bronchiectasis (widened airways that trap mucus). It is for adults who produce phlegm daily and have had at least two worsening episodes in the last year.
Hear when a new Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.